Last reviewed · How we verify

NCT06903416

Non-Invasive Neuromodulation for Upper Extremity Function in Spinal Cord Injury: A Crossover Trial

Recruiting now Phase 2, PHASE3 Last updated 22 May 2025
What this trial tests

Phase 2, PHASE3 trial testing Transcutaneous Cervical Spinal Cord Stimulation in Spinal Cord Injury Cervical in 10 participants. Currently enrolling.

Timeline
7 May 2025
Primary endpoint
30 March 2030
31 March 2030

Quick facts

Lead sponsorUniversity of Alberta
PhasePhase 2, PHASE3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposebasic science
Enrollment10
Start date7 May 2025
Primary completion30 March 2030
Estimated completion31 March 2030
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of Alberta

Who can join

Adults 18 to 75, any sex, with Spinal Cord Injury Cervical. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study explores two promising therapies for restoring arm and hand function in people with chronic cervical spinal cord injury (SCI), a condition that affects independence and quality of life. It will compare transcutaneous spinal cord stimulation and paired corticospinal-motoneuronal stimulation, both combined with rehabilitation. Using a crossover design, participants will receive each therapy for two months, with a one-month washout period in between. Safety, effectiveness, and patient-reported outcomes like daily living ability and quality of life will be assessed, alongside changes in neural excitability. The results of this study may enable us to tailor treatments to individual needs, promoting personalized care and improved outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injury Cervical

Currently open trials in the same condition.

Other University of Alberta trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06903416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing